BNET Industries

Market Cap:$80.1M
Last Fiscal Year Sales:$3.7M
  • Public
Dow Jones Description

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's key products are LibiGel (testosterone gel) in Phase III clinical development under an SPA, to treat female sexual dysfunction, and Elestrin (estradiol gel), FDA approved to treat hot flashes in menopausal women. The current market for testosterone and estrogen products is approximately $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction potentially adding $2.0 - $4.0 billion, and the current market for hormonal contraception is approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery systems and aesthetic medicine (BioLook ). On June 30th, 2009, BioSante announced entering into a definitive merger agreement with Cell Genesys (CEGE) in an all-stock transaction, with BioSante as the surviving company. The merged company will focus primarily on LibiGel, BioSante's testosterone gel in Phase III clinical development for the treatment of female sexual dysfunction (FSD). The merged company will also seek future development opportunities for Cell Genesys' GVAX Immunotherapies including potential combination with BioVant , BioSante's vaccine adjuvant, as well as possible external collaborations, and will also seek to outlicense other Cell Genesys technologies. ...

Vice Chairman, President and Chief Executive Officer
Stephen M Simes
Number of Employees 23
Contact Information

biosantepharma....

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

Recent Events

  • Developments for Parkinson's Disease Ignite Investor Enthusiasm

    11/16/09 - Merger / Acquisition - View Story

  • BioSante Pharmaceuticals Releases 3Q 2009 Financial Results

    11/12/09 - Financial Announcement - View Story

  • Rodman and Renshaw Initiates Coverage on Biosante Pharmaceuticals BPAX with an Outperform

    11/09/09 - Bond / Stock Rating - View Story

  • Cell Genesys merges wtih BioSante Pharmaceuticals

    10/15/09 - Joint Venture / Alliance - View Story

  • BioSante completes Cell Genesys merger

    10/14/09 - Board Member - Entering - View Story

  • BioSante completes Cell Genesys buyout

    10/14/09 - Merger / Acquisition - View Story

  • BRIEF-BioSante Pharmaceuticals and Cell Genesys announce final exchange ratio for merger

    9/22/09 - New Investment - View Story

  • BioSante and Cell Genesys Report Final Exchange Ratio for Merger

    9/25/09 - Merger / Acquisition - View Story

  • BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement

    8/29/09 - Joint Venture / Alliance - View Story

  • Biotech Stock Mailbag: Geron, Oculus, BioSante

    8/19/09 - Merger / Acquisition - View Story

  • BioSante Pharmaceuticals to Raise $12 Million in Registered

    8/13/09 - New Investment - View Story

  • BioSante, Cell Genesys merger will provide cash for Phase III

    8/10/09 - Merger / Acquisition - View Story

  • News and FDA Updates for BioMimetic (NASDAQ:BMTI), Neurogen (NASDAQ:NRGN), BioSante (NASDAQ:BPAX)

    8/08/09 - Financial Announcement - View Story

  • BUYINS.NET: BXC, AIS, SENO, DISK, ROIA Expected To Be Lower Leading Up To Next Earnings...

    7/30/09 - Joint Venture / Alliance - View Story

  • Company and People Notes: GSK and Chroma Form Development Pact; Siemen's Healthcare Appoints US CEO;...

    7/01/09 - Merger / Acquisition - View Story

  • BioSante and Cell Genesys sign merger agreement

    7/01/09 - Joint Venture / Alliance - View Story

  • BioSante Pharmaceuticals and Cell Genesys Ink Definitive Merger Pact

    7/07/09 - Merger / Acquisition - View Story

News & Analysis

biosante pharmaceutical inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Philip B Donenberg Cfo, Treasurer and Secretary
Phillip B Donenberg Chief Financial Officer, Treasurer and Secretary
Joy A. Thomas Vice President, Corporate Development
Michael Snabes Vice President, Clinical Dev
Bill Milling Controller and Senior Director of Operations
Alan Zachary
Ross J. Mangano Director
Victor Morgenstern Director

Board of Directors

Name (plus bio) Position
Stephen M Simes Vice Chairman, President and Chief Executive Officer
Fred Holubow Chairman
Louis W. Sullivan Board of Directors
Edward C. Rosenow Board of Directors
Peter Kjaer Board of Directors

Stephen M. Simes has served as our Vice Chairman, President and a director of our company since January 1998 and Chief Executive Officer since March 1998. From October 1994 to January 1997, Mr. Simes was President, Chief Executive Officer and a Director of Unimed Pharmaceuticals, Inc., a company with a product focus on infectious diseases, AIDS, endocrinology and oncology. From 1989 to 1993, Mr. Simes was Chairman, President and Chief Executive Officer of Gynex Pharmaceuticals, Inc., a company which concentrated on the AIDS, endocrinology, urology and growth disorders markets. In 1993, Gynex was acquired by Bio-Technology General Corp., and from 1993 to 1994, Mr. Simes served as Senior Vice President and Director of Bio-Technology General Corp. Mr. Simes' career in the pharmaceutical industry started in 1974 with G.D. Searle & Co.

Organization Position Status
Biosante Pharmaceuticals, Inc. Vice Chairman, President and Chief Executive Officer Current
Biosante Pharmaceuticals, Inc. Board of Directors Former

Phillip B. Donenberg, CPA has served as our Chief Financial Officer, Treasurer and Secretary since July 1998. Before joining our company, Mr. Donenberg was Controller of Unimed Pharmaceuticals, Inc. from January 1995 to July 1998. From 1993 to 1994, Mr. Donenberg was Controller of Molecular Geriatrics Corporation, a biotechnology corporation. Prior to Molecular Geriatrics Corporation, Mr. Donenberg held similar positions with other pharmaceutical companies, including Gynex Pharmaceuticals, Inc. and Xtramedics, Inc.

Organization Position Status
Biosante Pharmaceuticals, Inc. Cfo, Treasurer and Secretary Current

Organization Position Status
Biosante Pharmaceuticals, Inc. Chief Financial Officer, Treasurer and Secretary Current

Organization Position Status
Biosante Pharmaceuticals, Inc. Vice President, Corporate Development Current
Biosante Pharmaceuticals, Inc. Board of Directors Current
University of Chicago Master of Business Administration In International Business and Finance Former
University of Illinois Bachelor of Science Degree In Finance Former
University of Chicago Bachelor of Science Degree In Finance Former

Michael C. Snabes M.D., Ph.D. has served as our Vice President of Clinical Development since April, 2008. Dr. Snabes has served as a medical consultant to BioSante on clinical and regulatory matters since November, 2005. Dr. Snabes is a board certified reproductive endocrinologist, as well as holding a Ph.D. in physiology and reproductive endocrinology. Before joining our company, Dr. Snabes was an Associate Professor in the Section of Reproductive Endocrinology and Infertility in the Department of Obstetrics and Gynecology at The University of Chicago Pritzker School of Medicine. From 2003 to 2004, Dr. Snabes served as Medical Advisor in Clinical Research and Development in Inflammation, Arthritis, and Pain at Pfizer, Inc. and from 1999-2003 in the same position at Pharmacia, Inc. where he worked on the successful development of the COX-2 inhibitors, Celebrex and Bextra. From 1997 to 1999, Dr. Snabes served as Associate Director in Clinical Research in Women's Health at Searle/Monsanto. Dr. Snabes is an elected Fellow of the American College of Obstetrics and Gynecology, the American College of Surgeons and the American College of Endocrinology. Dr. Snabes is the author of more than 135 publications and abstracts.

Organization Position Status
Biosante Pharmaceuticals, Inc. Vice President, Clinical Dev Current
American College of Surgeons Fellow Current
Biosante Pharmaceuticals, Inc. Senior Medical Director Former
University of Chicago Pritzker School of Medicine Associate Professor Former
Pfizer Inc. Medical Advisor Former

Bill Milling, CPA, has served as our Controller and Senior Director of Operations since October, 2004. Before joining our company, Mr. Milling was the Controller of Dor BioPharma from March 2002 to September 2004. From 1994 to 2002, Mr. Milling was with CCH, Inc. where he held various financial and systems positions of increasing responsibility. Mr. Milling holds a Bachelor of Science degree in Accountancy from Eastern Illinois University.

Organization Position Status
Biosante Pharmaceuticals, Inc. Controller and Senior Director of Operations Current
Eastern Illinois University Bachelor of Science Degree In Accountancy Former

Organization Position Status
Biosante Pharmaceuticals, Inc. Current

Organization Position Status
Pegasus Associates Vice President Current
William Harris Investors, Inc. Managing Director Current
Pegasus Limited Founder Current
Biosante Pharmaceuticals, Inc. Chairman Current
Biosante Pharmaceuticals, Inc. Director Current
Pegasus Associates Co-Founder Former
Savient Pharmaceuticals, Inc. Board of Directors Former
Thermoretec Corp. Board of Directors Former

Louis Sullivan served as U.S. Secretary of Health and Human Services from 1989 to 1993. Prior to and following his service as HHS Secretary, he was President of Morehouse School of Medicine, which he now serves as President Emeritus. He is co-chair of The Presidential Advisory Council on HIV/AIDS. A graduate of Morehouse College, he earned his medical degree from Boston University, and is certified in internal medicine and hematology. The recipient of 45 honorary degrees, he served on the faculties of the medical schools at Harvard, Seton Hall, and Boston universities before arriving at Morehouse in 1975. He was also the founding president of the Association of Minority Health Professions Schools.

Organization Position Status
The National Health Museum, Inc U.S. Secretary of Health and Human Services Current
Caligor, Inc. Secretary Current
Biosante Pharmaceuticals, Inc. Board of Directors Current
McDonald's Corporation Current
Go Active Current
Protect The Truth Current
National Families In Action Current
Biosante Pharmaceuticals, Inc. Chair of Board Current
United Therapeutics Corporation Board of Directors Current
Jonas Center for Nursing Excellence Board of Directors Current
Consumer Health Services, Inc. Board of Directors Current
Emergent BioSolutions Inc. Director Current
The National Health Museum, Inc Board of Directors Current
Minority Health Board of Directors Current
Phi Beta Kappa Board of Directors Current
Henry Schein, Inc. Board of Directors Current
Inhibitex, Inc. Board of Directors Current
Antex Biologics, Inc. Director Current
Bristol-Myers Squibb Company Board of Directors Current
Georgia-Pacific Corporation Board of Directors Current
Boyscouts.Com Board of Directors Current
Inhibitex, Inc. Member Current
3M Company President Former
More House President Former
Boston City Hospital Founder Former
Medical Education Founder Former
Morehouse College Director of The Medical Education Program Former
Morehouse College Dean Former
Harvard Medical School Instructor Former
Morehouse School of Medicine Trustee Former
Morehouse School of Medicine President Former
Harvard Corporation Former
Equifax Inc. Board of Directors Former
3M Company Board of Directors Former
CIGNA Corporation Board of Directors Former
Human Services Inc Secretary Former
Health-Corp Secretary Former
Care and Company Board of Directors Former
Caligor, Inc. Secretary Former
Ethics Resource Center Board of Directors Former
Boston University M.D. Former
Morehouse College B.S. Former
Boston University Medical Degree Former
Boston University School of Medicine Degree Former

Edward C. Rosenow, III, M.D. has been a director of our company since November 1997. Dr. Rosenow is a Master Fellow of the American College of Physicians as well as Master Fellow the American College of Chest Physicians. Dr. Rosenow was the Arthur M. and Gladys D. Gray Professor of Medicine at the Mayo Clinic from 1988 until his retirement in 1996. Beginning with his residency in 1960, Dr. Rosenow has worked at the Mayo Clinic in many professional capacities including as a Consultant in Internal Medicine (Thoracic Diseases) from 1966 to 1996, an Assistant Professor, Associate Professor and Professor of Medicine at the Mayo Clinic Medical School, President of the Mayo Clinic Staff in 1986, and Chair of the Division of Pulmonary and Critical Care Medicine from 1987 to 1994. Dr. Rosenow has also served as a consultant to NASA, space station FREEDOM at the Johnson Space Center in Houston, Texas from 1989 to 1990 and as the President of the American College of Chest Physicians from 1989 to 1990. In 1998, he received the Mayo Distinguished Alumnus Award. Dr. Rosenow serves on the board of directors of Virex, Inc, a private company.

Organization Position Status
Biosante Pharmaceuticals, Inc. Board of Directors Current
Plexigen Inc. Board of Directors Current
American College of Physicians Fellow Current
American College of Chest Physicians President Former
Johnson Space Center Consultant Former
Mayo Clinic Arthur M. and Gladys D. Gray Professor of Medicine Former

Peter Kjaer has been a director of our company since July 1999. Mr. Kjaer has been President and Chief Executive Officer of Jet-Asia Ltd., a Hong Kong-based aircraft and management company, since April 1996.

Organization Position Status
Jet Asia Chief Executive Officer Current
Jet Asia President Current
Biosante Pharmaceuticals, Inc. Board of Directors Current

Ross Mangano was elected a director of our company in July 1999. Mr. Mangano has been the President and a director of Oliver Estate, Inc., a management company specializing in investments in public and private companies, since 1971. He serves on the board of directors of several private companies and U.S. RealTel Inc.

Organization Position Status
Biosante Pharmaceuticals, Inc. Director Current

Organization Position Status
Resolute Partners, LLC Managing Partner Current
Valor Equity Partners, L.P. Chairman Current
Illinois Institute of Technology Board of Directors Current
Astral Brands, LLC Board of Directors Current
Plastag Corporation Board of Directors Current
Biosante Pharmaceuticals, Inc. Director Current
Illinois Institute of Technology Trustee Current
Harris Associates Former
Oakmark Chairman Former
Valor LLC Chairman Former
N-Vest Corp Director Former
American University J.D. Former
American University Washington College of Law J.D. Former
Illinois Institute of Technology B.S. In Chemical Engineering Former

Executive News

  • BioSante Pharmaceuticals to Present at Upcoming Healthcare Conferences

    Pharma Live - 9/03/09 - View Story

  • BioSante Pharmaceuticals to Present at Upcoming Healthcare Conferences

    Business Wire - 9/02/09 - View Story

  • BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement

    NewsBlaze - 8/29/09 - View Story

  • Need Cash? Go Buy It.

    CFO.com - 8/27/09 - View Story

  • Biotech Stock Mailbag: Geron, Oculus, BioSante

    TheStreet.com - 8/19/09 - View Story

  • BioSante Pharmaceuticals Reports 100% Protection From H1N1 Challenge When Using BioVant Adjuvanted Vaccine

    Pharma Live - 8/19/09 - View Story

  • BioSante Pharmaceuticals Closes $12 Million Registered Direct Offering

    Pharma Live - 8/18/09 - View Story

  • BioSante Pharmaceuticals Closes $12 Million Registered Direct Offering

    Business Wire - 8/14/09 - View Story

  • BioSante Pharmaceuticals to Raise $12 Million in Registered

    Business Wire via MSN Money - 8/13/09 - View Story

  • BioSante Pharmaceuticals to Raise $12 Million in Registered Direct Offering

    Globe Investor - 8/13/09 - View Story

  • BioSante Pharmaceuticals to Raise $12 Million in Registered Direct Offering

    Business Wire - 8/13/09 - View Story

  • BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program

    Reuters - 8/13/09 - View Story

  • BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data in Phase III Program

    Forbes.com - 8/13/09 - View Story

  • BioSante Pharmaceuticals Reports Positive LibiGel Safety Data in Phase III Program

    Business Wire - 8/13/09 - View Story

  • BioSante, Cell Genesys merger will provide cash for Phase III

    FierceBiotech - 8/10/09 - View Story

  • BioSante Pharmaceuticals Reports Second Quarter 2009 Financial

    Business Wire via MSN Money - 8/07/09 - View Story

  • BioSante Pharmaceuticals Reports Second Quarter 2009 Financial Results

    Street Insider - 8/07/09 - View Story

advertisement
BPAX $1.51 -0.04 (-2.58% )
Volume 190,030
Shares Outstanding 53.0M
Market Cap 80.1M
Year High 2.70
Year Low 0.81
Earnings Per Share -0.58
P/E Ratio N/A
Dividend 0.00
Yield 0.00
advertisement